EGFR and non-small cell lung carcinoma: Osimertinib exhibited a pronounced impact compared to other EGFR-TKIs, presenting a ROR of 6.75 (99% CI: 5.29–8.62) relative to other NSCLC targeted therapies (ROR = 3.64, 99% CI: 2.94–4.50) and the full database (ROR = 5.37, 99% CI: 4.42–6.54, IC025 = 2.14).